Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN L A versus NALLPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN L A versus NALLPEN.
BICILLIN L-A vs NALLPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
NALLPEN (naloxone) is a competitive opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors, reversing the effects of opioid agonists including respiratory depression, sedation, and hypotension.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
1 gram IV every 8 hours over 30 minutes.
None Documented
None Documented
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
Terminal elimination half-life is 2.0-3.0 hours; prolonged in renal impairment (up to 24 hours).
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Primarily renal excretion (80-90% unchanged) with minor biliary/fecal elimination (5-10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic